Metraipolis › archive › dc_3d2e02e9417e

TALON phase IIIb study: 64 week results of brolucizumab versus aflibercept using treat-and-extend for neovascular age-related macular degeneration — Europe PMC PMID:41413355

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41413355
DOI
10.1038/s41433-[numero omesso]-x
License (as archived)
solo-consultazione
Archived
2026-11-07T13:21:18.943Z
SHA-256 of the archived text
5063ff219619a814a0749402300c2b03966ad1491a3d2e18297d6e4decc1c166
Stable URL of this page
https://metraipolis.com/documento/dc_3d2e02e9417e

How to cite

TALON phase IIIb study: 64 week results of brolucizumab versus aflibercept using treat-and-extend for neovascular age-related macular degeneration — Europe PMC PMID:41413355 — Europe PMC (en), https://europepmc.org/article/MED/41413355 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_3d2e02e9417e (Metraipolis archive dc_3d2e02e9417e, sha256 5063ff219619a814a0749402300c2b03966ad1491a3d2e18297d6e4decc1c166)
BibTeX
@misc{dc3d2e02e9417e,
  title = {TALON phase IIIb study: 64 week results of brolucizumab versus aflibercept using treat-and-extend for neovascular age-related macular degeneration — Europe PMC PMID:41413355},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41413355},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_3d2e02e9417e; sha256 5063ff219619a814a0749402300c2b03966ad1491a3d2e18297d6e4decc1c166},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41413355. Agents can read the archived copy with the MCP tool read_document.